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The glomerular ﬁltration barrier is aﬀected in a large number of acquired and inherited diseases resulting in extensive leakage
of plasma albumin and larger proteins, leading to nephrotic syndrome and end-stage renal disease. Unfortunately, the molecular
mechanisms governing the development of the nephrotic syndrome remain poorly understood. Here, I give an overview of recent
investigations that have focused on characterizing the interrelationships between the slit diaphragm components and podocytes-
secreted VEGF, which have a signiﬁcant role for maintaining the normal podocyte structure and the integrity of the ﬁltering
barrier.
1. Characteristicof the Glomerular Filtration
Barrierandthe SlitDiaphragm
The cells of the human body are surrounded by liquid
that is remarkably constant in its contents. The continued
regulation of the dissolved compounds and ions in this
internal environment is referred as homeostasis. Our kidneys
are extremely important in preserving the homeostasis. They
workrapidlyandsensitivelyinordertoregulatetheexcretion
of unwanted and toxic products resulting from tissue
metabolism, hence maintaining optimum concentration of
the ﬂuids, electrolytes, and acid-base in the body. The kidney
is formed by an estimated number of renal glomeruli of ∼1
million that ﬁltrate approximately 180 liters of plasma every
day, and only about 1.5–1.8 liters of this ﬁltrate are excreted
as urine. The plasma molecules are sieved through the renal
glomerular ﬁltration barrier based on their size and charge
[1]. This barrier is a highly specialized structure which con-
sistsofthreelayers:afenestratedendothelium,a300–350nm
thick glomerular basement membrane (GBM), and the
podocytes. The luminal side of the fenestrated endothelial
cells is covered by a layer of negatively charged membrane-
bound macromolecules(proteoglycans,glycosaminoglycans,
glycoproteins, and glycolipids) named glycocalyx, and it is
importantfortheselectivitypropertiesoftheglomerulus[2].
The GBM is composed of glycoproteins including type IV
collagen, laminins, entactin/nidogen, and heparin sulphate
p r o t e o g l y c a n ss u c ha sa g r i na n dp e r l e c a n .T y p eI Vc o l l a g e n
and laminins form complexes which are connected by
entactin/nidogen. This association plays an essential role
in size selectively restricting the passage of the proteins
throughtheglomerularﬁlter[3–5].Thepodocytesar ehighly
diﬀerentiated cells, and they are the visceral epithelial cells
of the kidney glomerulus. The podocytes project primary
processes from the cell body, which further branch into
numerous ﬁnger like processes called foot processes that
enwrap the glomerular capillaries. The neighboring foot
processes derived from diﬀerent cell bodies are connected
by a continuous adherent junction structure called the
slit diaphragm (SD) [6]. The apical membrane above the
SD is highly negatively charged mainly due to a heavily
sialylatedglycoproteinpodocalyxin[7].Thebasalmembrane
of podocyte foot processes serves to anchor podocytes to
the GBM via several adhesion molecules including α3β1-
integrin complex [8]a n dα-a n dβ-dystroglycans [9]. On the
other hand, the structure of the podocyte is maintained by a
complex cytoskeleton consisting of actin, myosin, α-actinin-
4, talin, and vinculin [10]. When podocytes are injured,
podocytes undergo a dramatic morphological change named
foot process eﬀacement resulting from alteration in its2 Journal of Signal Transduction
cytoskeletal structure and intercellular junctions. A direct
correlation between this process and the development of
proteinuria both in human disease and in experimental
models has been shown [11].
The slit diaphragm expresses several members of the
immunoglobulin (Ig) and cadherin superfamilies. Nephrin,
a member of the Ig superfamily, is a transmembrane protein
of 180kDa in humans, and it is posttranslationally modiﬁed
by N-glycosylation [12]. It has an extracellular segment
containing 8Ig-like domains, a ﬁbronectin domain and the
10 putative N-glycosylation sites, a transmembrane region,
and a short cytoplasmic segment [12–14]. It has been
shown that the N-glycosylation of nephrin is important
for its appropriate folding and localization in the plasma
membrane [15]. In 1998, it was suggested that nephrin is
the structural backbone of the slit diaphragm [12]. Several
studies have provided evidence that nephrin associates
with itself [16]. Nephrin has three “free” cysteines in the
extracellular domain, one in the Ig motif 1, one in the spacer
region between Ig motifs 6 and 7, and one in the ﬁbronectin
domain. These free cysteines residues in the extracellular
domain allow the alignment between nephrin molecules
from the neighboring foot processes in an antiparallel mode
and bridge the distance between interdigitating podocyte
foot processes [14, 17]. The cytoplasmic region of nephrin
contains nine conserved tyrosines residues, which could
become phosphorylated during the binding of nephrin
ligand and can serve as binding sites for the SH2 domains
of cytoplasmic targets [18–21]. The natural extracellular
ligands for nephrin remain unknown until now. In addition
to the glomerular podocytes of kidneys, nephrin is expressed
in the pancreas and in the nervous system [22]. Humans and
rodents also express a splice variant of nephrin that excludes
the transmembrane region [23]. Mutations of the nephrin
gene, NPHS1, produce congenital nephrotic syndrome of the
Finnish type (CNF) [12]. CNF is an autosomal, recessive
disorder, characterized by massive proteinuria in utero, and
the classical signs of nephrotic syndrome hypoalbuminemia,
hyperlipidemia, and edema developed within days after
birth. Kidney biopsy of children with CNF shows podocyte
foot process eﬀacement and absence of the slit diaphragms
[24]. The disease usually leads to death in the neonatal
period but can be treated with dialysis followed by kidney
transplantation in early childhood [25].
A growing number of proteins, including Neph1, the
classical P-cadherin that belongs to the Ig superfamily [6],
FAT-1 a nonclassical cadherin superfamily member [26],
and the tight junction protein ZO-1 [27] are localized at
the SD. In the SD, the cytoplasmic tail of nephrin interacts
with the adapter protein CD2-AP [28, 29], podocin [30, 31],
and the actin cytoskeleton via CD2-AP [32]. The C-terminal
domain of podocin interacts with nephrin, Neph1 [33],
and CD2-AP [30]. Neph1 also interacts with podocin [33]
and ZO-1 [34]. The canonical transient receptor potential 6
ion channel (TRPC6) interacts with podocin and nephrin
in the slit diaphragm [35]. Subsequently, it was shown
that mutations in several of these slit diaphragm-associated
proteins, including Neph1 [36], podocin [37], CD2-AP
[29], FAT-1 [38], and TRPC6 [39] results in eﬀacement
of podocytes, heavy proteinuria, development of nephrotic
syndrome, and early postnatal death in the majority on
the cases. In addition, mutations in α-actinin-4 [40], α3β1-
integrin [8], and podocalyxin [41] can lead to the same
phenotype. Taking together all these studies, it has been
proposed that the slit diaphragm plays a major role in
maintaining the ﬁltration barrier of the renal glomerulus.
However, the molecular components and function of the SD
remain incompletely characterized.
2.AlteredVEGF-AandSlitDiaphragmProtein
Levels CanCauseProteinuria
Several lines of evidence showed that vascular endothelial
growth factor A (VEGF-A), the best characterized angio-
genic/vasculogenic factor, is a critical “cross-talk” protein
among the three components of the glomerular ﬁltra-
tion barrier [42]. Patients who underwent chemotherapy
with anti-VEGF (e.g., bevacizumab, sunitinib) or receptor
tyrosine kinase inhibitors lead to proteinuria, podocyturia,
hypertension, edema, glomerular capillary endotheliosis,
and glomerular thrombotic microangiopathy indicating
damage to the glomerular ﬁltration barrier [43–46]. In addi-
tion, several reports showed that women with preeclampsia,
a condition characterized by excess circulating levels of a
soluble form of the VEGF receptor (sFlt-1, see below),
developed similar symptoms that are in VEGF ablation
therapy [47, 48]. Experiments with normal healthy mice
showed that intravenous infusion of sFlt-1 or anti-VEGF
antibodies causes glomerular endotheliosis and proteinuria
[49]. Taken together, these results emphasize the importance
of the regulation of VEGF-A signaling in the development of
proteinuria.
VEGF-A belongs to a family of multipotent cytokines.
Six diﬀerent VEGF-A isoforms and two known families can
be generated by alternative splicing of eight exons separated
by 7 introns of a single gene. The VEGFxxx family of
isoforms, where xxx refers to the number of amino acids,
is formed by diﬀerential splicing in exons 6 and 7 and the
proximal splice site in exon 8 (termed exon 8a). They are
named VEGF 121, 145, 165, 183, 189, and 206 based on
the number of amino acids in humans. Rodents present the
same number of isoforms, although they are one amino
acid shorter [50]. VEGF121,V E G F 165, and VEGF189 are the
most abundantly expressed isoforms, whereas VEGF145 and
VEGF206 are comparatively rare [50]. In human kidneys, the
mostabundantisoformsofVEGF-Aarestronglyexpressedin
podocytes and also in proximal and distal tubular cells [51].
Receptors for VEGF-A are vascular endothelial growth factor
receptor VEGFR-1 (also known as Flt-1) and VEGFR-2 (also
known as Flk-1), which are predominantly expressed on the
glomerular endothelial cells and pre- and postglomerular
vessels [51, 52]. These VEGF receptors belong to the PDGF
(platelet-derived growth factor) family of receptor tyrosine
kinase (RTKs, class III) and have a similar domain structure
[53]. VEGFR-1 and -2 contain three functional domains:
seven Ig-like extracellular domains, a single membrane
spanning region, and a cytoplasmic tyrosine kinase domainJournal of Signal Transduction 3
[54, 55]. Binding of growth factors to the second and
third immunoglobulin domains leads the receptors dimer-
ization, protein kinase activation, autophosphorylation, and
initiation of signaling pathways [56]. In addition to these
receptors tyrosine kinases, VEGFxxx interacts with a family
of coreceptors, the neuropilins (Np) [57]. Soluble truncated
forms of both VEGFR-1 and VEGFR-2 have recently been
found in plasma. Even though little is known about the
latter [58], the soluble form of the VEGF receptor-1 (sFlt-
1) is known to regulate VEGF activity by binding VEGF-A
in the circulation [59]. Park et al. proposed that full length
VEGFR-1 and sFlt-1 have a “decoy” function on the vascular
endothelium, where they exert a negative eﬀect on VEGF
activity, by preventing VEGF binding to VEGFR-2 [60].
Recently, another novel set of VEGF-A isoforms called
“VEGFxxxb” have been described. The VEGFxxxb family
is formed by splice variant using a distal site on exon 8
(termed exon 8b) [61, 62]. The VEGFxxxb transcripts code
for polypeptides with the same length as the classical ones,
because exon 8a and exon 8b have the same size. Therefore,
these isoforms were named VEGF121b, 145b, 165b, 183b,
189b, and 206b. Furthermore, it has been identiﬁed that
VEGFxxxbinteractswiththeVEGFR-2extracellulardomain,
resulting in diﬀerential downstream kinase activation, but
the “b-isoforms” are unable to bind Np [63]. VEGF165b was
the ﬁrst member of the VEGFxxxb family to be identiﬁed
and was discovered in human renal cortex [62]. This isoform
is expressed early in human kidney embryonic development
and is expressed endogenously in diﬀerentiated, but not
dediﬀerentiated human podocytes [64]. Schumacher et al.
demonstrated that in normal renal development, the capil-
lary loop stage showed the highest VEGF165 expression that
diminishes afterward with a switch in favor of the VEGF165b
isoform,whichshoweditshighestexpressioninadultcontrol
glomeruli[65].Severalreportshaveshownthattheinclusion
of exon 8a results in the conventional proangiogenic and
propermeability of VEGFxxx family but replacement of 8a
with exon 8b in the VEGFxxxb family produces peptides
that are antiangiogenic, inhibits permeability chronically,
and reduces rather than promotes tumor growth [66–68].
In renal-cell [62], prostate [69], colon carcinoma [70], and
malignant melanoma [71], VEGF165b has been reported to
be downregulated. A dysregulation of VEGFxxxb expression
was also observed in the glomeruli of humans with Denys-
Drash syndrome [65] and in human preeclamptic placentas
[72].
In addition to the renal lesion reported in preeclamp-
sia, altered levels of VEGF-A protein and/or mRNA
were detected in various human and rodent experimental
renal disease models associated with proteinuria. Diabetic
nephropathy is characterized by the development of protein-
uria followed by decreased glomerular ﬁltration in associa-
tion with glomerulosclerosis. Researchers have observed that
urinary VEGF [73, 74], renal and/or glomerular VEGF levels
and VEGF receptors are consistently increased in diverse
experimental models of diabetes, especially early in the
course of the disorder [75, 76]. In vitro, exposure of cultured
podocytes to high glucose concentrations also upregulates
VEGF expression [77]. Blocking the increased VEGF-A with
anti-pan-VEGF antibodies improves the diabetes-related
earlyrenaldysfunction[73,78].Consequently,theinhibition
of upregulated VEGF and its receptors resulted in beneﬁcial
eﬀects on diabetes-induced functional and structural alter-
ations.
Several types of glomerulonephritis, in which experi-
mental models or human kidney biopsies were analyzed,
showed contradictory results. Glomerulonephritis (GN) are
inﬂammatory glomerular diseases associated to proteinuria,
frequently leading to chronic disease progression and renal
replacement therapy. In some experimental models of
human minimal change nephropathy (MCN), VEGF and its
receptors were, as in diabetic nephropathy, upregulated and
correlated with the severity of proteinuria [79]. In patients
withMCNandnephroticsyndrome,theurinaryVEGFlevels
are increased and positively correlated with the degree of
proteinuria [80]. In situ hybridization studies revealed that
VEGF mRNA expression was upregulated in podocytes with
MCN [81]. Patients with congenital nephrotic syndrome
of the Finnish type showed a slightly increased VEGF
expression in glomeruli [82]. Recently, Hohenstein et al.
have found increased glomerular VEGF expression in biop-
sies from patients with endocapillary nephritis, membra-
noproliferative glomerulonephritis (MPGN), and crescentic
nephritis [83]. Biopsies from patients with membranous
glomerulonephritis (MGN) presented markedly increased
V E G Fp r o t e i ni np o d o c y t e s[ 83]. Depending on the degree
of the injury and inﬂammation in the glomeruli with
glomerulosclerosis, VEGFR-1 expression was increased on
various cell types in focal areas, and VEGFR-2 expression
was more prominent in podocytes of biopsies with GN
[83]. In contrast, other studies found either a reduction
or lack of changes in the VEGF-VEGFR system in exper-
imental or clinical studies of MGN [81, 84], MPGN [85,
86], crescentic glomerulonephritis [87], or focal segmental
glomerulosclerosis (FSGS) [76]. M¨ uller-Deile et al. reported
a clinical case with metastatic cancers, where after total
tumour nephrectomy, the patient developed FSGS and
podocyturia in association with tyrosine kinase inhibitor
treatments [88]. The downregulation of VEGF expression
was also reported in adriamycin nephropathy rats [89]a n d
puromycin aminonucleoside rats [90] with the progressive
aggravation of foot processes morphology and development
of proteinuria. These results suggest that VEGF might
exert multiple eﬀects on the glomerular pathophysiologic
processesandthattheexpressionbalanceofVEGFisessential
for preserving the normal glomerular ﬁltration function.
To demonstrate that VEGF-A signaling is a key for
proper maintenance of the glomerular ﬁltration barrier,
several animal studies have been performed. Eremina et
al. generated mice with gain or loss of function of VEGF
speciﬁcally in the podocyte [91], avoiding the embryo-
lethal eﬀects observed in VEGF-A knockout [92] and in
haploinsuﬃcient mice [93]. Mice with podocyte-speciﬁc
deletionofbothVEGFallelesdiedatbirthorwithin18hours
of birth with kidney failure and grossly abnormal glomeruli.
The glomeruli of these mice fail to form functional ﬁltration
barriers due to major defects in endothelial cell migration,
survival, and diﬀerentiation. Mice with podocyte-speciﬁc4 Journal of Signal Transduction
heterozygosity for VEGF developed proteinuria, endothe-
liosis, and bloodless glomeruli, characteristic ﬁndings in
patients with preeclampsia, which progressed to nephrotic
syndrome and followed by kidney failure [91]. Kitamoto
and colleagues administered VEGF-blocking antibodies to
murine pups and observed that the development of the
kidney was impaired in terms of glomerulogenesis and
nephrogenesis[94].Conversely,theoverexpressionofVEGF-
A in podocytes also resulted in a dramatic phenotype due to
a collapsing glomerulopathy and end-stage renal failure [91].
All these discoveries emphasize the role of VEGF-A in renal
glomeruli and demonstrate that a tight regulation of VEGF-
A signaling is required for development and maintenance of
the glomerular ﬁltration barrier.
Diﬀerent groups have examined the expression of slit
diaphragm proteins in acquired glomerular diseases where
theVEGFlevelsarealtered.Inbothexperimentalandhuman
diabetes, one of the several diseases involving a podocyte
injury, various groups have found nephrin in the urine,
downregulation of nephrin expression in the slit diaphragm
and decreased nephrin mRNA levels that inversely corre-
lated with the degree of proteinuria [95–98]. Moreover,
no changes in the expression of CD2AP and podocin in
podocytes from diabetic patients were observed [97]. How-
ever, reduction of the elevated concentrations of glycated
albumin in diabetes animals showed signiﬁcant reduction of
proteinuria and restoration of distorted glomerular nephrin
and VEGF expression [99]. Chun-Liang et al. demonstrated
that activation of Notch-1 signaling in high glucose (HG)-
treated human podocytes and in the glomeruli of diabetic
rats produces increased VEGF expression, nephrin down-
regulation, and increased apoptosis, while the inhibition of
Notch-1 signaling signiﬁcantly abrogated VEGF activation,
nephrin repression, and ameliorated proteinuria in HG-
stressed cells and in diabetic kidney [100]. Garovic et al.
reported that proteinuria in patients with preeclampsia is
associated with downregulation of podocyte foot process
proteins, asnephrin and synaptopodin [101].Koop etal.and
Fukuda et al. reported reduced nephrin expression at protein
and/or mRNA level in patients and animals with MCN,
and a signiﬁcant decrease in the expression of podocin,
podocalyxin and CD2AP was also seen in MCN [102–104].
Nevertheless, the genetic analyses of patients with MCN
revealed heterozygous amino acid changes in nephrin and
podocin, but no amino acid substitutions were detected
in Neph1 and CD2AP genes [105, 106]. On the other
hand, several reports have investigated the expression of
nephrin in others glomerulosclerosis diseases, which were
not always consistent. Furness et al. [107], Huh et al. [108],
Srivastava et al. [109], Wang et al. [110], and Doublier et
al. [111] reported a downregulation in nephrin expression
in patients with focal segmental glomerular sclerosis, MPGN
and membranous nephropathy (MN), whereas, as reported
by Patrakka et al. [112], Guan et al. [113], and Hingorani
et al. [114], no signiﬁcant changes were seen in expression
of nephrin at all. Hara et al. showed that blockage of VEGF
activity in rats with progressive GN resulted in massive
urinary protein excretion and downregulated expression of
nephrin [115]. No extensive changes in the expression of
others slit diaphragm proteins were observed in glomeru-
losclerosis [116, 117]. These discrepant results in some
nephrotic syndromes may be attributed to diﬀerences in
the degree of glomerulosclerosis and the methods used for
detecting protein expression. Clearly, these studies demon-
strate that disruption in VEGF levels are not only associated
with increased proteinuria but also with readjustment of
nephrin-dependent slit diaphragm structure. VEGF-nephrin
signaling in podocytes may act through one or more survival
signaling pathways, but these pathways are not full known.
3. Paracrineor AutocrinePodocytic
VEGF-VEGFRSystem?
During fetal development, the podocytes are one of the
cell types producing the largest amounts of VEGF-A. When
podocytes are fully diﬀerentiated, they continue to express
VEGF-A, even though absolute levels of expression decrease
[118]. The adjacent and nearby associated glomerular
endothelial cells express VEGFR-1 and VEGFR-2 tyrosine
kinase receptors [42, 91]. As a consequence, some authors
have speculated that in normal conditions, a paracrine
regulatory mechanism where the podocyte-secreted VEGF
can bind to VEGF receptors on mesangium or glomerular
endothelial cells. It is now broadly accepted that VEGF must
move in the opposite direction of the glomerular ﬁltrate
in order to bind to its receptors. This notion is supported
by the following studies. Quaggin group postulated that
since podocytes produce the constitutive highest levels of
VEGF, there is a concentration gradient favoring diﬀusion
of VEGF from the podocyte to the glomerular endothelial
cells in addition to the ﬁnding that the diﬀusion rate across
the glomerular basement membrane is the predominant
transport mechanism for solutes with the molecular radii
under 30 ˚ A while that of VEGF is about 26 ˚ A[ 45, 119].
Sison et al. [120] have found that induced whole-
body postnatal deletion of VEGFR-2 caused marked dam-
age in glomerular microvascular beds with loss of viable
endothelial cells, whereas the same authors have observed
nonthrombotic microangiopathy eﬀect in the glomeruli of
mice with whole body postnatal deletion of VEGFR-1 [120].
Eremina et al. showed that genetic inhibition of VEGF in
maturepodocytesalsoresultedinglomerularendothelialcell
damage and thrombotic microangiopathy [45]. In addition,
Sisonetal.observedthatthedeletionofVEGFR-2speciﬁcally
from podocytes never developed proteinuria or glomerular
injury, and the glomerular ﬁltration barrier was intact [120].
These observations support the idea that VEGF signaling
through VEGFR-2, not through VEGFR-1, is essential for
maintaining the glomerular ﬁltration barrier via a paracrine
mechanism.
Nephrin cytoplasmic domain has a series of conserved
tyrosine-basedmotifs[18],whicharephosphorylatedbyFyn
kinase and are able to bind and phosphorylate the Nck adap-
tor [19] and the cytoplasmic kinase phosphatidylinositol-
3-OH kinase (PI3K) proteins via their SH2 domains [20].
Phosphorylation of Nck contributes to the reorganization
of the actin cytoskeleton in podocytes [21], and phospho-
rylated PI3K stimulates the serine-threonine kinase AKTJournal of Signal Transduction 5
signaling, leading the phosphorylation of molecules involve
in the prevention of apoptosis and safeguard viability in
podocytes [20]. Interestingly, Foster et al. postulated that
VEGF treatment caused reduction of apoptosis through
nephrin phosphorylation together with a decrease in AKT-
signaling [121]. Sugimoto et al. observed that a single
intravenous infusion of anti-VEGF antibodies into normal
healthy mice produced excessive albumin excretion in the
urine, massive glomerular, endothelial cell damage, and
signiﬁcantly reduction of nephrin expression [49]. Also,
Foster et al. provided the ﬁrst evidence that in podocytes,
VEGFisassociatedwiththecellmembraneinnormalhuman
glomeruli[121].Thisphenomenoncouldbeexplainedeither
by an accumulation of VEGF protein before secretion or
by the sequestration of VEGF, via receptor binding, onto
the podocyte cell surface [122]. To answer these issues,
the same group observed that the addition of type III
receptortyrosine-kinaseinhibitorabolishedthereducingcell
death induced by VEGF, suggesting that a tyrosine kinase-
mediated receptor for VEGF-A exists on podocytes [122].
These results suggest that podocytes may have the potential
to bind the VEGF that they secrete. This hypothesis is
also supported by other independent groups. They observed
that, using transmission electron microscopy, VEGFR-2 is
e x p r e s s e di nm i c ep o d o c y t e sin vivo [123, 124]. Guan et
al. observed that VEGFR-2 mRNA levels are increased in
mouse-diﬀerentiated cultured podocytes [125], and recom-
binant VEGF165 induced VEGFR-2 mRNA and protein levels
and reduced apoptosis in these diﬀerentiated podocytes.
In contrast, VEGFR-2 was not detected in conditionally
immortalized human podocytes [122]. These discrepancies
may be species related. Nonetheless, M¨ uller-Deile et al.
identiﬁed that VEGFR-2 is the main receptor responsible
for the PI3K/AKT regulation and podocyte survival in
response to autocrine levels of VEGF-A and VEGF-C in
human podocytes in vitro [126]. VEGF-A signaling also
showed the ability to regulate slit diaphragm proteins by
inducingpodocinupregulationandincreasingitsinteraction
with CD2AP in vitro [125]. We have recently demonstrated
that transgenic mice overexpressing VEGF164 in podocyte
showed proteinuria, glomerular basement membrane thick-
ening, loss of slit diaphragms, podocyte eﬀacement, induced
VEGFR-2 phosphorylation, and downregulation of nephrin
expression [123]. Moreover, we provided the ﬁrst evidence
that nephrin, a podocyte-speciﬁc protein, and VEGFR-2
are associated in vivo, suggesting the expression of VEGFR-
2 in podocytes [123]. Podocyte-derived VEGF has a well-
documented paracrine function on endothelial cells as well
as an autocrine function on podocytes themselves. However,
several groups disagree with the idea of podocyte-VEGFR-
2 mediating the autocrine function of VEGF. Nevertheless,
all these data indicate not only that podocytes possess a
functional autocrine VEGF-A signaling through VEGFR-2
but also that VEGF-A signaling regulates the expression of
slit diaphragm proteins. Additionally, our studies do not
exclude the possible eﬀects of podocyte VEGF164 overexpres-
sionthroughVEGFR-1,whichisabletoregulateinanegative
fashion the activity of VEGF and thereby preventing VEGF
binding to VEGFR-2.
Although the podocyte has been described to be the site
of VEGF production within the glomerulus, the role and/or
interaction of podocyte-derived VEGF-A in glomerular
health and disease still remain debatable. In view of the
fact that VEGF receptors (VEGFR-1 and VEGFR-2) are
expressed at the highest levels on glomerular endothelial
cells, investigations have primarily focused on the paracrine
functions for podocyte-derived VEGF-A. At present, several
studiesdemonstratedthatVEGFR-2isexpressedatlowlevels
by podocytes and highlight the existence and importance of
autocrine podocytic VEGF-VEGFR system in normal and
injured podocytes. Disruption or an imbalance of podocyte-
derived VEGF-A produces changes in slit diaphragm pro-
teins, and, as consequence, it leads to podocyte eﬀacement
and proteinuria. Loss or failure of podocytes function
contributes to the development of glomerulosclerosis, which
is the ﬁnal stage of various renal diseases.
The biology of the VEGF-VEGFR system is indeed com-
plex. Any manipulation of this system has to be cautious in
order not to disrupt its fragile balance. To ﬁnd a therapeutic
strategy is going to be challenging, especially considering
the vast diversity of VEGF isoforms and because speciﬁc
compounds interfering with the VEGF-VEGFR system are
limited. Although data is currently unavailable in humans,
several strategies to either inhibit or enhance the VEGF axis
have shown promising results in animal models of renal
disease.
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